Total Payments
$52,936
2024 Payments
$4,832
Companies
6
Transactions
82
Payment Breakdown by Category
Consulting$29,073 (54.9%)
Research$12,582 (23.8%)
Travel$7,636 (14.4%)
Other$1,950 (3.7%)
Food & Beverage$1,695 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $29,073 | 14 | 54.9% |
| Unspecified | $12,582 | 16 | 23.8% |
| Travel and Lodging | $7,636 | 29 | 14.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,950 | 1 | 3.7% |
| Food and Beverage | $1,695 | 22 | 3.2% |
Payments by Type
General
$40,354
66 transactions
Research
$12,582
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31,291 | 45 | $0 (2024) |
| GlaxoSmithKline, LLC. | $6,239 | 13 | $0 (2018) |
| PFIZER INC. | $5,498 | 8 | $0 (2024) |
| F. Hoffmann-La Roche AG | $4,443 | 2 | $0 (2023) |
| Shire North American Group Inc | $3,125 | 13 | $0 (2017) |
| Genentech, Inc. | $2,340 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,832 | 4 | Merck Sharp & Dohme LLC ($2,932) |
| 2023 | $4,443 | 2 | F. Hoffmann-La Roche AG ($4,443) |
| 2022 | $7,703 | 11 | Merck Sharp & Dohme LLC ($7,703) |
| 2021 | $3,283 | 3 | Merck Sharp & Dohme Corporation ($3,283) |
| 2020 | $4,690 | 3 | Merck Sharp & Dohme Corporation ($2,350) |
| 2019 | $15,023 | 26 | Merck Sharp & Dohme Corporation ($15,023) |
| 2018 | $6,767 | 5 | GlaxoSmithKline, LLC. ($4,664) |
| 2017 | $6,195 | 28 | Shire North American Group Inc ($3,125) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,365.00 | General |
| 08/30/2024 | PFIZER INC. | — | — | In-kind items and services | $1,900.00 | Research |
| Study: PF06760805 CLINICAL PUBLICATION PROGRAM | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| 01/24/2024 | Merck Sharp & Dohme LLC | ROTATEQ (Biological), VAXNEUVANCE, VAXELIS | Food and Beverage | In-kind items and services | $6.92 | General |
| Category: VACCINE | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | Xofluza (Drug) | — | In-kind items and services | $1,927.74 | Research |
| Study: Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study • Category: Virology & Specialty Care | ||||||
| 03/31/2023 | F. Hoffmann-La Roche AG | Xofluza (Drug) | — | In-kind items and services | $2,515.01 | Research |
| Study: Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years • Category: Virology & Specialty Care | ||||||
| 11/01/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,290.00 | General |
| 11/01/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/24/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $178.61 | General |
| 10/24/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $74.25 | General |
| 10/24/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 10/23/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $514.90 | General |
| 10/23/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $366.69 | General |
| 10/23/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $315.35 | General |
| 10/23/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $143.32 | General |
| 10/23/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 03/11/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| 11/01/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 10/06/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 04/23/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,137.50 | General |
| 12/09/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| 07/15/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 05/21/2020 | Genentech, Inc. | Xofluza (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Virology & Specialty Care | ||||||
| 12/02/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| 12/02/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MENABCWY-006 BST:005 (V102_03E1) | GlaxoSmithKline, LLC. | $3,504 | 1 |
| Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years | F. Hoffmann-La Roche AG | $2,515 | 1 |
| Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study | F. Hoffmann-La Roche AG | $1,928 | 1 |
| PF06760805 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,900 | 1 |
| A Phase 3b, Controlled, Open Label, Multi Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline s Meningococcal ACWY Conjugate Vaccine Menveo , Administered to Healthy Individuals 15 through 55 years of age, approximate | GlaxoSmithKline, LLC. | $1,576 | 11 |
| MENACWY CONJ-038 (V59_77) | GlaxoSmithKline, LLC. | $1,159 | 1 |
About Dr. Stanley Block, MD
Dr. Stanley Block, MD is a Pediatrics healthcare provider based in Bardstown, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619974821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stanley Block, MD has received a total of $52,936 in payments from pharmaceutical and medical device companies, with $4,832 received in 2024. These payments were reported across 82 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($29,073).
Ad
Practice Information
- Specialty Pediatrics
- Location Bardstown, KY
- Active Since 07/01/2005
- Last Updated 02/07/2024
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1619974821
Products in Payments
- Xofluza (Drug) $6,783
- TRUMENBA (Biological) $3,598
- XIIDRA (Drug) $1,323
- ROTATEQ (Biological) $6.92
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Bardstown
Daniel Finn, Md, MD
Pediatrics — Payments: $19,369
Pediatrics $19,369
Dr. James Hedrick, Md, MD
Pediatrics — Payments: $18,975
Pediatrics $18,975
Lindsay Blackmon, Md, MD
Pediatrics — Payments: $504.79
Pediatrics $504.79
Rebecca Findlay, Md, MD
Pediatrics — Payments: $292.18
Pediatrics $292.18
Dr. Thomas Wagoner, Md, MD
Pediatrics — Payments: $13.05
Pediatrics $13.05
Robert Smith, Md, MD
Pediatrics — Payments: $11.78
Pediatrics $11.78